From The Retirement Nerds.
Medicare is positioning to cover GLP-1 drugs for weight loss through two programs. Starting July 1, 2026 the Bridge program will provide access to GLP-1 weight-loss drugs — including Foundayo, Wegovy, and Zepbound — for eligible beneficiaries at $50/month. But there are important details the headlines aren’t telling you about the tradeoffs of covering these types of medications.
RELATED VIDEO:
MEDICARE PLAYBOOK DOWNLOAD:
📋 CMS GLP-1 Bridge FAQ: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
📋 KFF Medicare GLP-1 Spending Trends: https://www.kff.org/medicare/recent-trends-in-glp-1-use-and-spending-in-medicare/
📋 KFF Medicaid GLP-1 Spending: https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
🔗 Get help with Medicare: https://theretirementnerds.com/
=============================
Send me a message!
Erik@TheRetirementNerds.com
=============================
============================================================
Join our newsletter for monthly tips, book recommendations, and personal stories!
============================================================
📌 Timestamps:
0:00 Intro
0:47 GLP-1 Medicare Cost Problem
1:11 Policy Decisions
2:27 The Two Programs
2:48 Bridge Details
4:20 Expensive Drug Problems
7:54 Impact on Advantage vs Supplement
10:31 Bigger Picture Problem
11:50 Where to Get Help
#Medicare #GLP1 #Wegovy #Zepbound #MedicareDrugs #RetirementNerds
Federal Disclaimer:
We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all your options.
